Andrographis,
does it really help with Reduction of common-cold symptoms and duration?
research showsAn independent meta-analysis of 33 RCTs and 7,175 participants found symptom-relief signals for cough at SMD -0.39 and sore throat at SMD -1.13, supporting B for relief. However, only four trials were placebo comparisons, 73% were unblinded, and combination products such as Kan Jang were included. Duration is C because I² was 96% to 98% and a manufacturer-sponsored 300-person trial was positive only on day 3. The overall grade is B with 60 points.
ads claimMarketed products use expressions such as 'immune support,' 'natural antiviral,' 'cold prevention,' and 'faster recovery.' The research scope is symptom scores and time to resolution over several days after a cold begins, which is distinct from evidence for preventing infection, clearing viruses, or preventing severe complications.
Useful facts when choosing a product
- Clinical trials include both single extracts standardized to andrographolides and fixed combinations containing Eleutherococcus.
- The 2023 single-extract trial used AP-Bio 200 mg/day and 400 mg/day for 7 days.
- Main outcomes included WURSS-21, cough, sore throat, overall symptom scores, and time to symptom resolution.
- Gastrointestinal symptoms and skin reactions were the main nonserious adverse events reported with oral preparations.
What the research actually shows
The independent Hu 2017 systematic review included 33 RCTs with 7,175 participants and reported cough at SMD -0.39 and sore throat at SMD -1.13. However, only four studies were placebo comparisons, 73% were unblinded, and combination products such as Kan Jang were included. Heterogeneity for symptom duration was I² 96% to 98%. The manufacturer-sponsored Raj 2023 RCT of 300 participants found a WURSS-21 difference only on day 3, with no difference on days 5 and 7.
Why this is classified as B (60)
Symptom relief is B on the independent cough and sore-throat meta-analysis, limited by only four placebo comparisons, 73% unblinded trials, and inclusion of combinations such as Kan Jang. Duration is C because I² was 96% to 98% and the manufacturer-sponsored 300-person trial was positive only on day 3. The overall result is B with 60 points.
Counterpoint. A short-term early symptom-relief signal, particularly for cough and sore throat, remains across several studies. This judgment does not generalize results from specific extracts to every andrographis product or to infection prevention.
Rejudgment record. Reassessment (cross-check reflected) — Symptom relief is B based on an independent meta-analysis of 33 RCTs and 7,175 participants, limited by four placebo comparisons, 73% unblinded trials, and combination products; duration is C because I² was 96% to 98% and the manufacturer-sponsored 300-person trial was positive only on day 3
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of common-cold symptoms | B | An independent meta-analysis and several RCTs show signals of improvement in cough, sore throat, and overall symptoms, but study quality and formulation heterogeneity are substantial. |
| Shortening symptom duration | C | Duration analyses had I² of 96% to 98%, and the manufacturer-sponsored 300-person trial differed only on day 3. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Hu XY et al. 2017 | Independent systematic review and meta-analysis | 7,175 | Independent UK NIHR SPCR funding | Cough, sore throat, overall symptoms, time to symptom resolution, and adverse events | Signals of improved cough and sore throat and shorter time to resolution versus placebo; overall methodological quality of included trials was poor. | Key |
| Melchior J et al. 2000 | Randomized double-blind placebo-controlled pilot and phase III trials | 179 | Unknown; commercial fixed-combination product | Patient symptom scores and physician diagnostic scores | Improved total symptom and diagnostic scores in the phase III trial; evidence came from an andrographis-Eleutherococcus fixed combination. | Supportive |
| Raj JP et al. 2023 | Phase III double-blind randomized placebo-controlled trial | 300 | Sponsored by Natural Remedies Private Limited | WURSS-21, nasal mucus weight, mucociliary clearance, and IL-8 | WURSS-21 was positive on day 3 but showed no between-group difference on days 5 and 7, and objective measures were not significant. | Key |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-13).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-13 · Corrections: none
Cite this verdict
[Chamgap] Andrographis (Andrographis paniculata) x reduction of common-cold symptoms and duration — Evidence Grade B·60. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/immunity/andrographis-common-cold-symptoms-duration/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.